Aeglea BioTherapeutics Investor Presentation Deck

Extensive discovery campaign pursued to identify an uncompromising TL1A antibody Heavily resourced campaign employing multiple strategies and formats enabled discovery of desirable TL1A clones Strategy 1 Strategy 2 Strategy 3 Strategy 4 SPYRE Format 1 Set A Set B Set C Set D Format 2 Set E Set F Format 3 Format 4 Set G Set H Set I 1000+ CLONES MONOMER AND TRIMER BINDER PICOMOLAR POTENCY EXTENDED HALF-LIFE POTENTIAL BEST-IN-CLASS TL1A 22

View entire presentation